Med. praxi. 2025;22(1):36-43 | DOI: 10.36290/med.2024.040

Primary osteoporosis in the general practitioner's office: treatment and prevention

prof. MUDr. Jan Štěpán, DrSc.
Revmatologický ústav, Praha

General practitioners and gynecologists provide treatment with oral aminobisphosphonates in people who, according to their medical history and results of clinical, laboratory, and bone densitometry examinations have primary (involutionary or postmenopausal) osteoporosis, or have suffered a low-traumatic fracture but do not have a very high risk of fractures. Patients who are diagnosed or suspected of secondary osteoporosis and patients with a very high risk of fractures in primary osteoporosis are referred to outpatient specialists. In particular, however, general practitioners and gynecologists have an unmistakable position in the early prevention of primary and secondary osteoporosis, which remains a decisive measure for reducing the incidence of low-traumatic fractures due to the cost of screening, diagnosis, and treatment of the disease in a large population of people over 50 years of age. The article mentions the population-based program for early detection of osteoporosis, recommended procedures, and practical aspects of the treatment of primary osteoporosis using oral aminobisphosphonates.

Keywords: primary osteoporosis, secondary osteoporosis, aminobisphosphonates.

Received: September 10, 2024; Accepted: September 27, 2024; Published: February 20, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpán J. Primary osteoporosis in the general practitioner's office: treatment and prevention. Med. praxi. 2025;22(1):36-43. doi: 10.36290/med.2024.040.
Download citation

References

  1. Kanis JA, Cooper C, Rizzoli R, et al. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int. 2017;28(7):2023-34. Go to original source... Go to PubMed...
  2. Kanis JA, Norton N, Harvey NC, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16(1):82. Go to original source... Go to PubMed...
  3. Vytřísalová M, Toušková T, Fuksa L, et al. How General Practitioners and their patients adhere to osteoporosis management: A follow­‑up survey among Czech General Practitioners. Front Pharmacol. 2017;8:258. Go to original source... Go to PubMed...
  4. Palička V, Rosa J, Pikner R, et al. Centrum doporučených postupů pro praktické lékaře. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Osteoporóza. Novelizace 2023. SVL ČLS JEP: Praha 2023. ISBN 978-80-88280-51-4. Available from: https://smos.cz/wp content/uploads/2023/12/doporucene_postupy_osteoporoza_2023.pdf>.
  5. SMOS, SPL, SSG, VZP. Metodika realizace populačního programu časného záchytu osteoporózy v ČR2023. Available from: https://media.vzpstatic.cz/media/Default/dokumenty/mso/metodika screening osteoporoza_1-4 2023.pdf>.
  6. Dejdarová L, Halata D, Bezdíčková L,et al. Centrum doporučených postupů pro praktické lékaře. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Osteoporóza. Doplněk 2024. SVL ČLS JEP: Praha 2024. ISBN 978-80-88280-51-4. Available from https://www.svl.cz/svl docs/doporucene postupy/45/dp osteoporoza 2024.pdf.
  7. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-102. Go to original source... Go to PubMed...
  8. Zima T, Springer D, Vítek L, et al. Centrum doporučených postupů pro praktické lékaře. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Laboratorní metody. SVL ČLS JEP: Praha 2024. ISBN 978-80-88280-47-7. Available from: https://www.svl.cz/svl­‑docs/doporucene­‑postupy/41/laboratorni­‑metody-2023.pdf.
  9. Sheu A, White CP, Center JR. Bone metabolism in diabetes: a clinician's guide to understanding the bone­‑glucose interplay. Diabetologia. 2024;67(8):1493-506. Go to original source... Go to PubMed...
  10. Dusilová Sulková S, Pokorná A, Šafránek R, et al. Kostní nemoc při selhání ledvin - renální i non­‑renální komponenta. Vnitř Lék. 2021;67(5):258-63. Go to original source...
  11. JEP ČČ. Diagnostika a léčba postmenopauzální osteoporózy. In: Doporučené postupy ČGPS ČLS JEP. Sbírka doporučených postupů č. 4/2022. Available from: https://cgps.cz/doporučené postupy/jiné/diagnostika a léčba postmenopauzalní osteoporozy/?layout=default.
  12. Demay M, Pittas A, Bikle D, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907-47. Go to original source... Go to PubMed...
  13. Adler RA, El­‑Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long­‑term bisphosphonate treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. Go to original source... Go to PubMed...
  14. Trajanoska K, Schoufour JD, de Jonge EAL, et al. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study. Bone. 2018;114:116-24. Go to original source... Go to PubMed...
  15. Štěpán JJ, Hrušková H, Kverka M. Update on Menopausal Hormone Therapy for Fracture Prevention. Curr Osteoporos Rep. 2019;17(6):465-73. Go to original source... Go to PubMed...
  16. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22. Go to original source... Go to PubMed...
  17. Lakatos P, Takacs I, Marton I, et al. A Retrospective Longitudinal Database Study of Persistence and Compliance with Treatment of Osteoporosis in Hungary. Calcif Tissue Int. 2016;98(3):215-25. Go to original source... Go to PubMed...
  18. Freemantle N, Cooper C, Diez­‑Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta­‑analysis. Osteoporos Int. 2013;24(1):209-17. Go to original source... Go to PubMed...
  19. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41. Go to original source... Go to PubMed...
  20. Pavelka K, Vencovský J, Horák P, et al. Revmatologie. Praha: Maxdorf Jessenius; 2018. 733 p.
  21. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.